Treatment of Inflammatory Bowel Disease with Biologics

Author:   Adam S. Cheifetz ,  Joseph D. Feuerstein
Publisher:   Springer International Publishing AG
Edition:   1st ed. 2018
ISBN:  

9783319602752


Pages:   335
Publication Date:   22 November 2017
Format:   Hardback
Availability:   Manufactured on demand   Availability explained
We will order this item for you from a manufactured on demand supplier.

Our Price $310.47 Quantity:  
Add to Cart

Share |

Treatment of Inflammatory Bowel Disease with Biologics


Add your own review!

Overview

Full Product Details

Author:   Adam S. Cheifetz ,  Joseph D. Feuerstein
Publisher:   Springer International Publishing AG
Imprint:   Springer International Publishing AG
Edition:   1st ed. 2018
Weight:   6.432kg
ISBN:  

9783319602752


ISBN 10:   3319602756
Pages:   335
Publication Date:   22 November 2017
Audience:   Professional and scholarly ,  Professional & Vocational
Format:   Hardback
Publisher's Status:   Active
Availability:   Manufactured on demand   Availability explained
We will order this item for you from a manufactured on demand supplier.

Table of Contents

Mechanism of Action and Pharmacokinetics of Biologics.- Anti-tumor Necrosis Factor Agents in Ulcerative Colitis.- Anti-tumor Necrosis Factor Agents in Crohn’s Disease.- Anti-TNF Therapy for Treatment of Extraintestinal Manifestations of Inflammatory Bowel Disease.- Use of Biologics in the Postoperative Management of Crohn’s Disease.- Biologics in Pregnancy and Breastfeeding.- Concomitant Use of Immunosuppressive Therapy with Tumor Necrosis Factor (TNF) Antagonists in Inflammatory Bowel Disease.- Therapeutic Drug Monitoring of Biologic Agents.- Use of Biologics in Crohn’s Disease and Ulcerative Colitis Prior to Surgery and Perioperative Risks.- Cessation of Biologics – Can it be Done?.- Biologic Therapy in Pediatric Inflammatory Bowel Disease.- Infectious Complications of Biologics.- Tumor Necrosis Factor-Alpha Inhibitors and Risks of Malignancy.- Non-infectious and Non-malignant Complications of Biologics.- Biosimilars in Inflammatory Bowel Disease 2017: State of the Science, State of the Art, State of the Finances.- Anti-Integrin Agents in IBD: Efficacy and Risk of Complications.- Novel Agents in Inflammatory Bowel Disease.- Quality, Safety, and Practical Considerations of Using Biologic Therapies. 

Reviews

Author Information

Adam S. Cheifetz, MD Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA Joseph D. Feuerstein, MD Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA

Tab Content 6

Author Website:  

Customer Reviews

Recent Reviews

No review item found!

Add your own review!

Countries Available

All regions
Latest Reading Guide

MRG2025CC

 

Shopping Cart
Your cart is empty
Shopping cart
Mailing List